Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug ESK-001 put to the test in Long-Term safety study

NCT ID NCT05739435

Disease control Sponsor: Alumis Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study is checking the long-term safety and effectiveness of the drug ESK-001 (envudeucitinib) for people with plaque psoriasis. It includes 165 adults who have already completed a previous ESK-001 study. Participants will take the drug as an oral tablet and be monitored for side effects and changes in their psoriasis symptoms and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
envudeucitinib (ESK-001) oral tablet
What this could lead to
If successful, this could confirm ESK-001 as a safe and effective long-term treatment option for plaque psoriasis, helping patients manage their symptoms.
What could go wrong
This is a Phase 2 open-label extension study, not a large Phase 3 trial. It only includes people who already tolerated ESK-001, so results may not apply to all patients. Long-term safety data is still being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

165 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have completed a prior ESK-001 study * Men and Women must use highly effective methods of contraception for the entirety of the study Exclusion Criteria: * Pregnancy * Received a prohibited concomitant medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • Investigator SIte#1036

    Overland Park, Kansas, 66210, United States

  • Investigator Site # 1006

    San Antonio, Texas, 78213, United States

  • Investigator Site # 1011

    Columbus, Indiana, 47201, United States

  • Investigator Site # 1012

    Rapid City, South Dakota, 57702, United States

  • Investigator Site # 1013

    Tampa, Florida, 33614, United States

  • Investigator Site # 1023

    Rogers, Arkansas, 72758, United States

  • Investigator Site # 1029

    Birmingham, Alabama, 35205, United States

  • Investigator Site # 1041

    South Jordan, Utah, 84095, United States

  • Investigator Site # 2002

    Waterloo, Ontario, N2J 1C4, Canada

  • Investigator Site # 2004

    Mississauga, Ontario, L4Y 4C5, Canada

  • Investigator Site # 2007

    North Bay, Ontario, PiB 3Z7, Canada

  • Investigator Site # 2008

    Surrey, British Columbia, V3V 0C6, Canada

  • Investigator Site # 2010

    Québec, Quebec, G1V 4X7, Canada

  • Investigator Site #1001

    Phoenix, Arizona, 85032, United States

  • Investigator Site #1002

    Sherman Oaks, California, 91403, United States

  • Investigator Site #1005

    Rolling Meadows, Illinois, 60008, United States

  • Investigator Site #1007

    Santa Monica, California, 90404, United States

  • Investigator Site #1010

    Clarkston, Michigan, 48346, United States

  • Investigator Site #1015

    Houston, Texas, 77056, United States

  • Investigator Site #1017

    Owensboro, Kentucky, 42301, United States

  • Investigator Site #1018

    Los Angeles, California, 90045, United States

  • Investigator Site #1019

    Portland, Oregon, 97223, United States

  • Investigator Site #1021

    Encinitas, California, 92024, United States

  • Investigator Site #1022

    Philadelphia, Pennsylvania, 19103, United States

  • Investigator Site #1025

    Hialeah, Florida, 33012, United States

  • Investigator Site #1026

    Rockville, Maryland, 20850, United States

  • Investigator Site #1027

    South Bend, Indiana, 46617, United States

  • Investigator Site #1031

    New Brighton, Minnesota, 55112, United States

  • Investigator Site #1033

    Norman, Oklahoma, 73071, United States

  • Investigator Site #1035

    Macon, Georgia, 31217, United States

  • Investigator Site #1043

    Sandy Springs, Georgia, 30328, United States

  • Investigator Site #2001

    Edmonton, Alberta, T6G 1C3, Canada

  • Investigator Site #2003

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Investigator Site #2005

    Oakville, Ontario, L6J 7W5, Canada

  • Investigator Site #2006

    London, Ontario, N6H 5L5, Canada

  • Investigator Site #2009

    Toronto, Ontario, M3H 5Y8, Canada

  • Investigator site # 1028

    Miami, Florida, 33175, United States

  • Investigator site # 1030

    Fort Lauderdale, Florida, 33308, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.